CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH Jul 12, 2018
CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions Jun 25, 2018
CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions May 29, 2018
CohBar, Inc. Announces Closing of Private Placement for Aggregate Gross Proceeds of Approximately $3,900,000 Apr 13, 2018
